JP2022511568A5 - - Google Patents

Info

Publication number
JP2022511568A5
JP2022511568A5 JP2021533154A JP2021533154A JP2022511568A5 JP 2022511568 A5 JP2022511568 A5 JP 2022511568A5 JP 2021533154 A JP2021533154 A JP 2021533154A JP 2021533154 A JP2021533154 A JP 2021533154A JP 2022511568 A5 JP2022511568 A5 JP 2022511568A5
Authority
JP
Japan
Prior art keywords
composition according
smad4
subject
glial
under conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511568A (ja
JP7518547B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065742 external-priority patent/WO2020123663A1/en
Publication of JP2022511568A publication Critical patent/JP2022511568A/ja
Publication of JP2022511568A5 publication Critical patent/JP2022511568A5/ja
Priority to JP2024104638A priority Critical patent/JP2024129091A/ja
Application granted granted Critical
Publication of JP7518547B2 publication Critical patent/JP7518547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533154A 2018-12-11 2019-12-11 統合失調症及び他の神経精神障害の治療方法 Active JP7518547B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024104638A JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778145P 2018-12-11 2018-12-11
US62/778,145 2018-12-11
PCT/US2019/065742 WO2020123663A1 (en) 2018-12-11 2019-12-11 Methods of treating schizophrenia and other neuropsychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024104638A Division JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Publications (3)

Publication Number Publication Date
JP2022511568A JP2022511568A (ja) 2022-01-31
JP2022511568A5 true JP2022511568A5 (OSRAM) 2022-12-15
JP7518547B2 JP7518547B2 (ja) 2024-07-18

Family

ID=69160318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533154A Active JP7518547B2 (ja) 2018-12-11 2019-12-11 統合失調症及び他の神経精神障害の治療方法
JP2024104638A Pending JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024104638A Pending JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Country Status (7)

Country Link
US (1) US20220025379A1 (OSRAM)
EP (1) EP3894556A1 (OSRAM)
JP (2) JP7518547B2 (OSRAM)
CN (2) CN119925614A (OSRAM)
AU (1) AU2019396450B2 (OSRAM)
CA (1) CA3122289A1 (OSRAM)
WO (1) WO2020123663A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9709553B2 (en) 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
WO2014124087A1 (en) 2013-02-06 2014-08-14 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
JP7457505B2 (ja) 2017-05-10 2024-03-28 ユニバーシティー オブ ロチェスター 神経精神障害を処置する方法
KR20210054502A (ko) 2018-06-21 2021-05-13 유니버시티 오브 로체스터 헌팅턴병을 치료하거나 이의 발병을 저해하는 방법
CN118924886A (zh) * 2023-03-16 2024-11-12 郑州大学 肿瘤共享新抗原表位肽或其编码核酸的新用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
PT1152009E (pt) 1999-02-12 2005-03-31 Sankyo Co Novos analogos de nucleosidos e oligonucleotidos
US6013787A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad4 expression
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
SG146682A1 (en) 2003-09-18 2008-10-30 Isis Pharmaceuticals Inc Modulation of eif4e expression
US7128264B2 (en) 2004-07-23 2006-10-31 Symbol Technologies, Inc: Electro-optical reader with improved performance in high intensity ambient light
JP4428296B2 (ja) 2005-06-10 2010-03-10 セイコーエプソン株式会社 表示パネルモジュールおよび表示装置
US9962558B2 (en) * 2005-08-05 2018-05-08 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
EP3399025B1 (en) 2007-03-23 2025-05-07 Wisconsin Alumni Research Foundation Somatic cell reprogramming
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2010017562A2 (en) 2008-08-08 2010-02-11 Mayo Foundation For Medical Education And Research Induced pluripotent stem cells
US20120276070A1 (en) 2009-11-17 2012-11-01 Vitro Diagnositics, Inc. Induced Pluripotent Stem Cells and Related Methods
EP2526189B1 (en) 2010-01-22 2016-10-12 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
US9228188B2 (en) * 2011-06-21 2016-01-05 Alnylam Pharmaceuticals, Inc. Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
CN113528442A (zh) * 2011-11-04 2021-10-22 纪念斯隆-凯特琳癌症中心 用于植入的中脑多巴胺（da）神经元
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2016115558A2 (en) 2015-01-16 2016-07-21 Bruno Doiron Compositions and methods for creating pancreatic cancer animal model

Similar Documents

Publication Publication Date Title
Xu et al. Current knowledge of microglia in traumatic spinal cord injury
JP7406793B2 (ja) ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
EP3394259B1 (en) Compositions and methods for decreasing tau expression
JP2021529169A5 (OSRAM)
CN111433361B (zh) 天使综合征反义治疗
PE20211749A1 (es) Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos
TWI462741B (zh) 使用微rna 195提供神經保護作用的方法
JP2011515357A5 (OSRAM)
JP2022511568A (ja) 統合失調症及び他の神経精神障害の治療方法
JP2009533475A5 (OSRAM)
WO2024238828A3 (en) Gene editing systems and compositions for treatment of hemoglobinopathies and methods of using the same
US10947538B2 (en) Allele-specific gene suppression
JP2023506842A5 (OSRAM)
KR20240099216A (ko) 슈반 세포로의 표적화 전달을 위한 설계자 세포외 소낭
CN116376910B (zh) 一种三叉神经痛的标志物及治疗三叉神经的药物
JP2021527649A5 (OSRAM)
CN103656685B (zh) microRNA-219在制备抗癫痫药物中的应用
JP2024515289A5 (OSRAM)
MX2022003108A (es) Composicion y metodo para inhibir la acumulacion, agregacion y formacion de ovillos de proteina tau.
RU2839721C2 (ru) Антисмысловые олигонуклеотиды, нацеленные на ген cav3.1, и их применения
US12589133B2 (en) Methods of downregulating CCL20 genes for treatment of traumatic brain injuries
WO2019186559A1 (en) Microglia modulators for use in treatment of depression
CN106075392B (zh) 促红细胞生成素衍生物在听力保护上的应用
WO2024259063A2 (en) Antisense oligonucleotides as fragile x syndrome therapeutics
US11230711B2 (en) Inhibition of LET7I as a means to enhance the protective effect of progesterone against stroke